Uses
PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns).
Source: US FDA prescribing information
Molecule
Prednisolone
Also known as prednisolone acetate, prednisolone sodium phosphate
- Presentations
- 17
- Brands
- 3
- Manufacturers
- 2
- Available from stock
- 0
Prednisolone is a corticosteroid indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). MedsAcross supplies Prednisolone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Corticosteroid, Corticosteroid Hormone Receptor Agonists
- ATC classification
- A07EA01 Prednisolone · Diarrhoea treatments and intestinal anti-inflammatories, subgroup A07E, subgroup A07EAC05AA04 Prednisolone · Vein and capillary protectors, subgroup C05A, subgroup C05AAD07AA03 Prednisolone · Corticosteroids for the skin, subgroup D07A, subgroup D07AAD07XA02 Prednisolone · Corticosteroids for the skin, subgroup D07X, subgroup D07XAH02AB06 Prednisolone · GlucocorticoidR01AD02 Prednisolone · Topical decongestant, subgroup R01ADS01BA04 Prednisolone · Eye medicines, subgroup S01B, subgroup S01BAS01CB02 Prednisolone · Eye medicines, subgroup S01C, subgroup S01CBS02BA03 Prednisolone · CorticosteroidS03BA02 Prednisolone · Corticosteroid
- US FDA first approval
- 22 May 1955
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral, Ophthalmic
- Dosage forms
- Oral solution, Ophthalmic suspension, Orally disintegrating tablet, Tablet, Eye drops, Syrup
- Identifiers
- UNII 9PHQ9Y1OLMRxCUI 8638CAS 50-24-8DrugBank DB00860Q11426176
Clinical information
From the regulator-approved product information. Each section names its source.
Dosing overview
Shake well before using. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.
Source: US FDA prescribing information
Contraindications
PRED MILD ® suspension is contraindicated in acute untreated purulent ocular infections, in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. PRED MILD ® suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
Source: US FDA prescribing information
Warnings and precautions
Prolonged use of corticosteroids may result in posterior subcapsular cataract formation and may increase intraocular pressure in susceptible individuals, resulting in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections. If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently. Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation.
Source: US FDA prescribing information
Side effects
The following adverse reactions have been identified during use of PRED MILD ®. Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions include elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing. The development of secondary ocular infection (bacterial, fungal, and viral) has occurred. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used.
Source: US FDA prescribing information
Storage
Store at 15°C to 25°C (59°F to 77°F) in an upright position. Protect from freezing.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
17 presentations of Prednisolone, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Prednisolone 15 mg/5 mL oral solutionOral Cold chainGeneric name | — | US FDA | Available on request |
| Prednisolone 10 mg/mL ophthalmic suspensionOphthalmicGeneric name | — | US FDA | Available on request |
| Prednisolone 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Prednisolone 5 mg/5 mL oral solutionOral Cold chainGeneric name | — | US FDA | Available on request |
| Prednisolone 10 mg/5 mL oral solutionOralGeneric name | — | US FDA | Available on request |
| Prednisolone 20 mg/5 mL oral solutionOral Cold chainGeneric name | — | US FDA | Available on request |
| Prednisolone 25 mg/5 mL oral solutionOral Cold chainGeneric name | — | US FDA | Available on request |
| Pred Mild 1.2 mg/mL ophthalmic suspensionOphthalmic | Allergan | US FDA | Available on request |
| Prednisolone 15 mg/5 mL syrupOralGeneric name | — | US FDA | Available on request |
| Orapred ODT 10 mg orally disintegrating tabletOral | Advanz Pharma | US FDA | Available on request |
| Orapred ODT 15 mg orally disintegrating tabletOral | Advanz Pharma | US FDA | Available on request |
| Orapred ODT 30 mg orally disintegrating tabletOral | Advanz Pharma | US FDA | Available on request |
| Pred Forte 10 mg/mL ophthalmic suspensionOphthalmic | Allergan | US FDA | Available on request |
| Prednisolone 10 mg orally disintegrating tabletOralGeneric name | — | US FDA | Available on request |
| Prednisolone 10 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Prednisolone 15 mg orally disintegrating tabletOralGeneric name | — | US FDA | Available on request |
| Prednisolone 30 mg orally disintegrating tabletOralGeneric name | — | US FDA | Available on request |
Brands by market
3 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 22 May 1955 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Prednisolone in public data. This is not a list of approved uses, see the clinical information.
Acquired hemophilia Acute graft versus host disease Adult-onset Still's disease Allergy Anasarka Autoimmune hemolytic anemia Autoimmune hepatitis B-cell lymphoma Bullous pemphigoid Cancer Collagen disease Conjunctivitis Diffuse large B-cell lymphoma Drug reaction with eosinophilia and systemic symptoms Enthesopathy Eye disease Eye inflammation Functional gastrointestinal disorder Giant cell arteritis Graft-versus-host disease Granulomatosis with polyangiitis Hematopoietic system disease Hemorrhagic fever with renal syndrome Hypersensitivity IgG4-related disease Inflammation Interstitial lung diseaseRare disease Leprosy Lymphoma Membranous glomerulonephritis Myasthenia gravis Nephrotic syndromeRare disease Non-Hodgkin lymphoma Polymyalgia rheumatica Polymyositis Pyoderma gangrenosum Skin disease Systemic-onset juvenile idiopathic arthritis Ulcerative colitis Uveitis
Questions and answers
Is Prednisolone available for export from India?
Yes, on request. MedsAcross lists 17 presentations of Prednisolone and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Prednisolone have?
The catalogue lists 3 brand names for Prednisolone, including Orapred ODT, Pred Forte, Pred Mild.
Is Prednisolone approved by the US FDA?
Yes. The US FDA first approved Prednisolone on 22 May 1955, according to Drugs@FDA.
Does Prednisolone need cold chain shipping?
At least one listed presentation of Prednisolone must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Which ATC class is Prednisolone in?
Prednisolone is classified under ATC code A07EA01 (Prednisolone).
References
- PRED MILD prescribing information (Allergan). U.S. National Library of Medicine, DailyMed. Retrieved 25 November 2025
Request Prednisolone for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.